´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18
±³À°ÀÏÀÚ : 2021-09-18
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5Ãþ ±×·£µåº¼·ë
±³À°ÁÖÁ¦ : ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ
´ã´çÀÚ : ¹éÁöÀº
¿¬¶ôó : 02-3275-5335
À̸ÞÀÏ : kshf4@kshf.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í ±³¼ö: 70,000¿ø, ÀϹÝÀÇ: 30,000¿ø, Àü°øÀÇ, °£È£»ç, 65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:00~10:30 Optimal HFrEF Treatment, New Perspectives James Januzzi(Harvard University USA)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:30~11:00 Role of SGLT2I from Chronic to Acute HF, Where Is Proper Position in GDMT? Michael Bohm(Saarland University Germany)
Åä·Ð 09-18 ±×·£µåº¼·ë 11:00~11:20 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 09-18 ±×·£µåº¼·ë 11:20~11:30 Break Time ()
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:30~11:45 Smartphone Application for Cardiac Rehabilitation: Strength and Weakness ±èÀÀÁÖ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:45~12:00 Skeletal Muscle and Prognosis of HF: Can Cardiac Rehabilitation Overcome Muscle Wasting? Kazunori Shimada(Juntendo University Hospital Japan)
Åä·Ð 09-18 ±×·£µåº¼·ë 12:00~12:10 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
½Ä»ç 09-18 ±×·£µåº¼·ë 12:10~13:00 Lunch ()
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:00~13:50 Brigntening Abstract Presentation (II) ()
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:50~14:10 Challenge of Prescribing Inertia: from CHAMP-HF Registry Biykem Bozkurt(Baylor College of Medicine HoustonTX)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:10~14:25 Performance Measures for HF Management in Korea À±Á¾Âù(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:25~14:45 Benefits of Quadruple Therapy for HFrEF JoAnn Lindenfeld(Vanderbilt University Medical Center Nashville TN)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:45~15:00 Comprehensive or Stepwise Treatment for HFrEF ÃÖÁ¤Çö(ºÎ»êÀÇ´ë)
Åä·Ð 09-18 ±×·£µåº¼·ë 15:00~15:20 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 09-18 ±×·£µåº¼·ë 15:20~15:30 Break Time ()
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:20~15:35 Benefit of SGLT2 Inhibitors across the Cardiorenal Continuum ±ÇÇõ»ó(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:35~15:50 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Non-cardiac effect ÃÖ¼ºÈñ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:50~16:05 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Cardiac Effect Á¶Àͼº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 16:05~16:20 Positioning of SGLT2 Inhibitors in HF Management: How Should We Sequence? John McMurray(Univ of Glasgow. UK)
Åä·Ð 09-18 ±×·£µåº¼·ë 16:20~16:50 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 09-18 ±×·£µåº¼·ë 16:50~17:00 Break Time ()
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:00~17:15 Ischemic Cardiomyopathy Yuhui Zhang(CHFA China)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:15~17:30 Idiopathic Dilated Cardiomyopathy ÀÌ»ó¾ð(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:30~17:45 Acute and Chronic Myocarditis Jian Zhang(CHFA China)
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:45~18:00 Hypertrophic Cardiomyopathy ±èÀÎö(°è¸íÀÇ´ë)
Åä·Ð 09-18 ±×·£µåº¼·ë 18:00~18:30 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)